Akero Therapeutics (AKRO) stock surged 5.82% in pre-market trading on Tuesday, fueled by analyst optimism following the release of promising late-stage trial data for the company's investigational drug efruxifermin.
Multiple analysts raised their price targets and reiterated Buy/Overweight ratings on AKRO, citing the positive 96-week results from the SYMMETRY trial evaluating efruxifermin for the treatment of non-alcoholic steatohepatitis (NASH).
Notably, Morgan Stanley significantly increased its price target to $96 from $46, with analysts highlighting efruxifermin's potential to capture significant market share and achieve commercial success if approved. Analysts at Canaccord Genuity, Citigroup, and H.C. Wainwright also raised their price targets, maintaining Buy ratings on the stock.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。